2,6-dimethyl-2H-chromene | 29415-77-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 2,6-dimethyl-2H-chromene
• 英文别名: 2,6-dimethyl-2H-chromene；2,6-Dimethyl-chromen-(3)
• CAS: 29415-77-8
• 化学式: C₁₁H₁₂O
• 分子量: 160.216
• InChiKey: SIOGASNAGPHUTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,6-dimethyl-2H-chromene 在 N-溴代丁二酰亚胺(NBS) 、 水 、 对甲苯磺酸 作用下， 以 二甲基亚砜 、 甲苯 为溶剂， 反应 1.0h， 生成 3-bromo-2,6-dimethyl-2H-1-benzopyran
  参考文献：
  名称：

  Allenes from 3-bromo-2H-1-benzopyrans

  摘要：

  The anionic cleavage of 2H-1-benzopyrans results in the formation of allenes.

  DOI：

  10.1039/p19940001733
• 作为产物：
  描述：

  2-(buta-1,3-dienyl)-4-methylphenol 以 N,N-二甲基甲酰胺 为溶剂， 以80%的产率得到2,6-dimethyl-2H-chromene
  参考文献：
  名称：

  高度官能化 (Z)-2-(Buta-1,3-dienyl) 苯酚和 2-Methyl-2H-chromenes 的新一锅合成方法：使用胺、钌和碱催化

  摘要：

  一种用于合成高度取代的苯并[b]氧杂环庚烷 5、(Z)-2-(buta-1,3-dienyl)phenols 6 和 2-methyl-2H-chromenes 7 的实用且简单的一锅多催化工艺首次通过闭环复分解/碱诱导开环/[1,7]-σ-σ 氢位移反应从简单的起始材料中获得。描述了通过碱诱导的高度官能化苯并 [b] 氧杂环庚烷 5 开环合成特权 (Z)-2-(buta-1,3-dienyl)phenols 6 (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 魏因海姆，德国，2008）

  DOI：

  10.1002/ejoc.200800472

文献信息

• A New Synthesis of<i>o</i>-Quinonemethides and Their Inter- and Intramolecular Cyclization Reactions
  作者：Tsutomu Inoue、Seiichi Inoue、Kikumasa Sato

  DOI：10.1246/bcsj.63.1062

  日期：1990.4

  The reaction of o-[1-(alkylthio)alkyl]phenols with silver(I) oxide at room temperature generated o-quinonemethides in good yields along with silver alkanethiolate. This mechanism, based upon one-electron oxidation, is excluded in view of several experimental facts. The resulting o-quinonemethides reacted efficiently with ethyl vinyl ether to afford cis-chromans as the result of endo cycloaddition between (E)-o-quinonemethides and the ether. Similarly, o-[1-(alkylthio)allyl]phenols were converted to cis-chromans via the corresponding (E)-o-quinonemethides (6-allylidenecyclohexadienone). In the absence of dienophiles, some chromenes were obtained from the allylphenols.

  室温下，o-[1-(烷硫基)烷基]苯酚与氧化银反应，能以良好产率生成邻醒甲叉中间体和银的烷硫醇盐。根据几个实验事实，基于单电子氧化的机制被排除。生成的邻醒甲叉中间体能高效地与乙基乙烯基醚反应，通过邻醒甲叉中间体与醚的endo环加成反应，生成顺式色满。类似地，o-[1-(烷硫基)烯丙基]苯酚通过相应的邻醒甲叉中间体(6-烯丙叉环己二烯酮)转化为顺式色满。在没有双烯亲和物存在时，从烯丙基苯酚获得了一些色烯。
• HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS
  申请人：Nishino Taito

  公开号：US20120128640A1

  公开（公告）日：2012-05-24

  An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells containing a compound represented by the formula (I) (wherein X, Y, Z, Ar 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R6 and R 7 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof, which can expand hematopoietic stem cells and/or hematopoietic progenitor cells.

  提供一种用于改善基因治疗中将基因转移至造血干细胞以治疗各种疾病的血液干细胞和/或造血祖细胞扩张剂。该扩张剂包含由式(I)表示的化合物（其中X、Y、Z、Ar1、R1、R2、R3、R4、R5、R6和R7如描述中所定义）、该化合物的互变异构体、前药或药学上可接受的盐或其溶剂，能够扩张血液干细胞和/或造血祖细胞。
• INOUE, TSUTOMU;INOUE, SEIICHI;SATO, KIKUMASA, BULL. CHEM. SOC. JAP., 63,(1990) N, C. 1062-1068
  作者：INOUE, TSUTOMU、INOUE, SEIICHI、SATO, KIKUMASA

  DOI：——

  日期：——
• METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND
  申请人：Nissan Chemical Industries, Ltd.

  公开号：EP2218716B1

  公开（公告）日：2016-11-16
• METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND
  申请人：Nishino Taito

  公开号：US20100266556A1

  公开（公告）日：2010-10-21

  An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various hematopoietic disorders is provided. A method for expanding hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises culturing hematopoietic stem cells and/or hematopoietic progenitor cells ex vivo in the presence of a compound represented by the formula (I) (wherein X, Y, X, Ar 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.